RecruitingPhase 1Phase 2NCT06878742

Dose-finding for Dobutamine During Transitional Circulation in Very Preterm Infants

Dose-finding for Dobutamine During Transitional Circulation in the Very Preterm Infant

Sponsor

Instituto de Investigación Hospital Universitario La Paz

Enrollment

30 participants

Start Date

Jun 24, 2024

Study Type

INTERVENTIONAL

Conditions

Infant, Premature, Diseases Circulatory and Respiratory Physiological Phenomena

Summary

Single centre, dose finding trial to establish the minimum effective dose of dobutamine required to treat hemodynamic insufficiency, defined as low superior vena cava (SVC) flow, in infants below 33 weeks' gestation during transitional circulation (first 72 hours from birth).

Eligibility

Max Age: 72 Hours

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Intravenous dobutamine 10 mcg/kg/min, a drug called Intravenous dobutamine 12.5 mcg/kg/min, and others for people with circulatory and respiratory physiological phenomena and infant, premature, diseases. The study is currently recruiting participants at 3 locations. People eligible for this study include up to age 72 Hours.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.